Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19

Clinical trial NCT06057064 · COMPLETED

Trial details

NCT number: NCT06057064
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

COVID-19, SARS-CoV-2

Start date: 2023-09-29
Primary completion: 2024-05-17
Enrollment: 116

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.